MiR-194-5p enhances the sensitivity of nonsmall-cell lung cancer to doxorubicin through targeted inhibition of hypoxia-inducible factor-1

World J Surg Oncol. 2021 Jun 14;19(1):174. doi: 10.1186/s12957-021-02278-3.

Abstract

Background: Despite chemotherapy being a common treatment, an increase in chemoresistance over time is unavoidable. We therefore investigated the role of miR-194-5p in regulating chordoma cell behavior and examined the downstream effectors of miR-194-5p.

Methods: In this study, NSCLC cell lines A549 and H460 were cultured under hypoxic conditions for 1 week to induce drug resistance to doxorubicin (DOX). The connection between miR-194-5p and HIF-1 was revealed by reverse transcription and real-time polymerase chain reaction (RT-qPCR), western blot, and dual-luciferase assays. We used TUNEL staining and the CCK-8 test to assess the sensitivity of NSCLC cells to DOX.

Results: We found that hypoxia-induced NSCLC cells enhanced resistance to DOX. MiR-194-5p was substantially reduced, and HIF-1 was increased in hypoxia-induced drug-resistant NSCLC cells. Moreover, miR-194-5p successfully induced NSCLC cell apoptosis by directly inhibiting HIF-1, thereby enhancing DOX sensitivity.

Conclusions: MiR-194-5p enhanced the sensitivity of NSCLC cells to DOX by directly inhibiting HIF-1. This work provides insights into underlying treatments for drug-resistant NSCLC.

Keywords: Doxorubicin resistance; HIF-1; NSCLC; miR-194-5p.

MeSH terms

  • A549 Cells
  • Cell Line, Tumor
  • Doxorubicin / pharmacology
  • Humans
  • Hypoxia-Inducible Factor 1*
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • MicroRNAs* / genetics
  • Prognosis

Substances

  • HIF1A protein, human
  • Hypoxia-Inducible Factor 1
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • MIRN194 microRNA, human
  • MicroRNAs
  • Doxorubicin